Cholic acid (Orphacol) - Laboratoires CTRS

Drug Profile

Cholic acid (Orphacol) - Laboratoires CTRS

Alternative Names: Orphacol

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratoires CTRS
  • Developer Laboratoires CTRS; Medical Need
  • Class Choleretics; Cholic acids; Gallstone therapies; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor modulators; Sodium-bile acid cotransporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn genetic disorders
  • New Molecular Entity No

Highest Development Phases

  • Marketed Inborn genetic disorders

Most Recent Events

  • 15 Feb 2017 Zaphyr Pharmaceuticals and Laboratoires CTRS enter into supply and distribution agreement for Cholic acid (Orphacol) in Middle East and North Africa for Inborn genetic disorders
  • 31 May 2016 Launched for Inborn genetic disorders in Germany (PO) before May 2016
  • 12 Sep 2013 Registered for Inborn genetic disorders (inborn errors in primary bile acid synthesis) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top